FDA recently amended the emergency use authorization for Pfizer and BioNTech’s COVID-19 vaccine booster to include individuals 5– 11 years of age at least five months after completing the...
FDA recently approved Eli Lilly and Company’s Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes as an addition to diet and...
Roche’s Global Access Program and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, recently partnered to build and strengthen diagnostic capacity and pandemic preparedness in...
Johnson & Johnson recently appointed Thibaut Mongon as chief executive officer and Paul Ruh as chief financial officer designate of its future consumer health company.
With over 20...
The Janssen Pharmaceutical Companies of Johnson & Johnson recently terminated its collaboration with Bavarian Nordic, which developed potential vaccines against the hepatitis B virus and human...
FDA recently limited the authorized use of Johnson & Johnson's COVID-19 vaccine to include individuals 18 years of age and older for whom other authorized or approved vaccines are not...
Pfizer recently announced that its COVID-19 treatment, Paxlovid reduced disease by 32% and 37% in adults for 5–10 days, respectively, compared to placebo.
The Phase 2/3 EPIC-PEP study...
FDA recently expanded the approval for COVID-19 treatment, Veklury (remdesivir), to include pediatric patients 28 days of age and older weighing at least seven pounds.
The agency's decision...
Pfizer and Valneva recently reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
The Phase 2 trial, VLA15-221, is the first clinical study with VLA15 that enrolled...
Moderna recently announced that Arpa Garay will join the company as chief commercial officer, effective May 31, 2022.
Garay joins Modera from Merck & Co, where she became an expert in oncology,...
FDA recently issued an emergency use authorization (EUA) for the first COVID-19 test that detects chemical compounds in breath samples associated with SARS-CoV-2 infection.
Qualified,...
Because the past few centuries have witnessed several revolutionary scientific advances, research into the mechanisms responsible for infectious diseases and the development of drugs and vaccines has led to the eradication of...
Moderna recently dosed the first patients in a Phase 1/2 study of its influenza mRNA vaccine candidates, mRNA-1020 and mRNA-1030.
The randomized, observer-blind trial will evaluate the safety,...
The World Health Organization (WHO) recently updated the emergency use listing (EUL) for Johnson & Johnson’s COVID-19 vaccine, recommending it as a booster in individuals 18 years of age and...
Merck recently reaffirmed its commitment to enable broad equitable access to its human papillomavirus (HPV) vaccines.
Under the initiative, Merck will expand its vaccines manufacturing facility...
FDA recently amended the emergency use authorization of Moderna's COVID-19 vaccine to allow for a second booster dose at the 50 microgram level in adults 50 years of age and older.
The...
Moderna will expand its mRNA vaccine pipeline through two new development programs, including a combination respiratory vaccine candidate and a program against four endemic human coronaviruses...
Pfizer and BioNTech recently submitted an application to FDA for emergency use authorization (EUA) of an additional COVID-19 vaccine booster dose for adults 65 years and older.
The...
Novavax recently launched its global, unbranded vaccine programs, 'We Do Vaccines' and 'Know Our Vax' as educational efforts to help protect people's health in the fight against the...
Moderna recently dosed the first participant in an HIV trimer mRNA vaccine (mRNA-1574) clinical trial.
The open-label Phase 1 trial will evaluate the safety and immunogenicity of...
